

## Tonix Pharmaceuticals to Participate in BIO CEO & Investor Digital Conference

CHATHAM, N.J., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will participate in the BIO CEO & Investor Digital Conference being held February 16-18, 2021.

The Company's presentation will be made through the BIO CEO & Investor Digital Conference website and available on demand to registered participants during the conference at <a href="https://www.bio.org/events/bio-ceo-investor-digital-conference/company-presentations">https://www.bio.org/events/bio-ceo-investor-digital-conference/company-presentations</a>. Following the conference, the presentation will be available under the IR Events tab of the Investors section of the Tonix website at <a href="https://www.tonixpharma.com">www.tonixpharma.com</a>.

## **About Tonix Pharmaceuticals Holding Corp.**

Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing small molecules and biologics to treat and prevent human disease and alleviate suffering. Tonix's portfolio is primarily composed of central nervous system (CNS) and immunology product candidates. The CNS portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. Tonix's lead CNS candidate, TNX-102 SL<sup>1</sup>, is in mid-Phase 3 development for the management of fibromyalgia, and positive data on the RELIEF Phase 3 trial were recently reported. The Company expects interim data from a second Phase 3 study, RALLY, in the second guarter of 2021<sup>2</sup> and topline data in the fourth guarter of 2021. The immunology portfolio includes vaccines to prevent infectious diseases and biologics to address immunosuppression, cancer, and autoimmune diseases. Tonix's lead vaccine candidate, TNX-1800<sup>3</sup>, is a live replicating vaccine based on the horsepox viral vector platform to protect against COVID-19, primarily by eliciting a T cell response. Tonix expects efficacy data from animal studies of TNX-1800 in the first quarter of 2021. TNX-801<sup>3</sup>, live horsepox virus vaccine for percutaneous administration, is in development to protect against smallpox and monkeypox.

This press release and further information about Tonix can be found at

<sup>&</sup>lt;sup>1</sup>TNX-102 SL is an investigational new drug and has not been approved for any indication.

<sup>&</sup>lt;sup>2</sup>Pending submission and agreement from FDA on statistical analysis plan.

<sup>&</sup>lt;sup>3</sup>TNX-1800 and TNX-801 are investigational new biologics and have not been approved for any indication.

## www.tonixpharma.com.

Jessica Morris (corporate) Tonix Pharmaceuticals investor.relations@tonixpharma.com (862) 904-8182

Olipriya Das, Ph.D. (media) Russo Partners Olipriya.Das@russopartnersllc.com (646) 942-5588

Peter Vozzo (investors) Westwicke, an ICR Company peter.vozzo@westwicke.com (443) 213-0505



Source: Tonix Pharmaceuticals Holding Corp.